cations from prospective training programs could be received; the first approval for a training program is expected shortly after June 2000. Approval is expected to lead to entry of the first trainee as early as July 2001. These target dates could change if issues arise with respect to the application, although this is not expected.
The MGP training programs are to be equal and joint functions of the Departments of Medical/Human Genetics (or equivalent) and Pathology in the institutions that house them. Applicants to the training program, which will be of 1 year's duration, must possess the M. D. or D. O. degree, have been certified by their respective Board, and have a valid unrestricted current license to practice medicine or osteopathy in a state of the United States or in Canada. Certification will depend on completion of a logbook of at least 150 cases completed during the residency period and not from archival sources, confirmation of successful completion of the training program by that program's director, three letters of recommendation from individuals certified in the subspecialty or in the specialty of either sponsoring Board, and successful passage of a written or computer-based examination created by members of the examination committee and administered in a secure setting. For the first 5 years of the subspecialty, board-certified Pathologists and Medical Geneticists with 2 or more years of experience in molecular genetic pathology may be eligible for an experience-based route to certification, which will differ only in that they will not be required to complete the training program.
A joint examination committee, consisting of members of both Boards with experience in molecular genetic diagnostic testing, is assembling a catalog of questions appropriate for the examination. Current plans call for this examination to be administered electronically through the facilities of ABP. After the training program requirements and curriculum have been approved by ACGME, the examinations can be constructed. Examinations should be available at about the time training programs open, so that individuals credentialed by experience to take the examination may do so. The frequency with which examinations will be administered remains to be established and will probably depend on the number of MGP program graduates after the first 2 to 3 cycles.
The draft description of the training program requirements will be available shortly from both Boards. Requests for these draft documents should be directed to The American Board of Medical Genetics (fax: 301-571-1895) or The American Board of Pathology (telephone: 813-289-5279). It is appropriate for training faculty in candidate institutions to plan for the creation of programs in Molecular Genetic Pathology and for their financing.
Editor's Note:
Dr. Byers is both a pathologist and a medical geneticist. He was Editor-in-Chief of the American Journal of Human Genetics and is a past president of the American Board of Medical Genetics. He was a member of the team of geneticists and pathologists who set up the guidelines for the program in Molecular Genetic Pathology. Publication of Dr. Byers' report is timely as several Pathology Departments around the country are considering the establishment of this new training program. A new companion to The American Journal of Pathology, The Journal of Molecular Diagnostics, will cover the area of molecular genetic pathology applied to diagnosis. The first issue of The Journal of Molecular Diagnostics will be published in November 1999.
